Touchlight

Touchlight is a private biotechnology company that has developed a disruptive, cell-free platform for manufacturing synthetic DNA (dbDNA™). This technology addresses critical bottlenecks in genetic medicine by providing a faster, more scalable, and higher-purity alternative to traditional plasmid DNA. The company operates as a contract development and manufacturing organization (CDMO) and technology provider, with its dbDNA™ already supporting nine clinical-stage programs for partners across various modalities, including AAV, mRNA, and lentiviral vectors. Its business model focuses on enabling partners to accelerate and de-risk the development of advanced therapies.

Proprietary, cell-free enzymatic platform for manufacturing synthetic DNA vectors (dbDNA™ and mbDNA™), eliminating bacterial fermentation.

Touchlight competes with traditional plasmid DNA manufacturers (e.g., Aldevron, Charles River's Vigene, Thermo Fisher) and CDMOs with large-scale fermentation capacity. It also faces potential competition from other synthetic biology firms developing alternative DNA writing/printing technologies. Its key differentiation is the enzymatic, cell-free production of GMP-grade DNA, offering advantages in speed, scalability, and purity.